2nd Quarter 2018 MD&A 11 2019 Guidance Update Strong industry fundamentals and enhanced visibility of earnings Outlook for 2019 raised: core EBITDA anticipated to increase 74% on 2017 to $1.75
September 2017 in comparison with the corresponding period last year ending 30 September 2016 We have committed ourselves to strategies that emphasized on building up strong fundamentals in order to drive our
level. We also had to cut costs in all areas, suspend our investment plan and reserve cash to maintain a strong finance position during the crisis. Cost of Sales and Gross Profit The gross profit margin
or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In
comparison with the corresponding period last year ending 30 June 2016 We have committed ourselves to strategies that emphasized on building up strong fundamentals in order to drive our businesses towards a
strong fundamentals in order to drive our businesses towards a sustainable growth organization. Our domestic performance has been invigorated by the product strategies that are not only limited to rolling
per kilogram in 1Q2018 or increased by 23.75%, overall, the cost of sales for 1Q2018 contributed of 86.88% of total sales, raised from 84.72% in 1Q2017. Gross Profit The consolidated gross profit in
contributed of 85.24% of total sales, raised from 83.68% in 2Q2017 while gross profit margin contributed about 14.76% in 2Q2018, decreased from 16.32% in 2Q2017. Cost of sales for 6M2018 was THB 6,833.64
kilogram in 3Q2018 or increased by 8.04%. Consequently, cost of sales for 3Q2018 contributed of 84. 37% of total sales, raised from 81. 92% in 3Q2017 while gross profit margin contributed of 15.63% in 3Q2018
issuance in the fourth quarter of 2015 did not appear in the company’s financial statements. Such circumstance caused KC financial statements to materially contain false information and raised doubts